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Introduction
Patients with concomitant cardiac and hematologic disorders presenting for
non-cardiac surgery are challenging to even the most experienced anesthesiologists.
Understanding the rationale of a patient’s therapy and calculating the risk of
changing this regimen in the perioperative period is essential. This chapter will
focus on several of the more common disorders and will discuss strategies to
optimize care in patients with coexisting cardiac and hematologic disease.

Sickle Cell Anemia
Sickle cell disease results from a variety of inherited genetic mutations in the
hemoglobin beta (HBB) gene resulting in defective beta-globin synthesis and
culminating in attenuated oxygen transport. One particular HBB gene mutation
produces an altered beta-globin molecule known as hemoglobin S (Hb S). Two
genotypes are expressed: 1) heterozygous (sickle cell trait) or 2) homozygous
(sickle cell disease).
Sickle Cell Disease
The clinical characteristics of sickle cell disease (SCD) include anemia and
recurrent vaso-occlusive crisis that commonly affect the cardiac, pulmonary, renal,
neurologic, and musculoskeletal systems. A growing body of literature suggests,
within the natural history of SCD, cardiovascular disease may play a role in disease
progression and early mortality 1 . In a cohort study of 240 patients with SCD,

cardiopulmonary compromise resulted in 39.5% of the recorded mortalities 1 .
Causes of cardiovascular mortality include myocardial ischemia, malignant
arrhythmia, heart failure, and pulmonary hypertension.
Chronic anemia of SCD results in an increased cardiac output and
intravascular volume retention to maintain oxygen delivery. Increased
intravascular volume results in left ventricular dilation and eccentric hypertrophy.
Arrhythmias, including atrial fibrillation, supraventricular tachycardia, and
ventricular fibrillation frequently arise secondary to chronic volume overload and
have been linked to cardiovascular mortality. Baseline QT prolongation has been
reported in 38% of pediatric and young adult patients with SCD 2 . Left ventricular
systolic function is typically preserved; however, myocardial hypertrophy and
increased LV mass lead to diastolic dysfunction and increased LV filling pressure.
Diastolic dysfunction has been associated with increased age, hypertension, and
renal failure and has been identified as an independent risk factors for mortality in
patients with SCD 3,4 .
Chronic hemolytic anemia results in release of free hemoglobin and other red
blood cell intracellular enzymes that inhibit nitric oxide signaling pathways causing
vasoconstriction 3 . Within the pulmonary vasculature, this mechanism is
responsible for the development of primary pulmonary hypertension. Pulmonary
hypertension, either secondary to volume overload and underlying diastolic heart
failure, or as a primary pathology, is encountered in up to 60% of adult patients with
SCD and contributes to early cardiovascular mortality

5,6

. Increased pulmonary

pressures should be treated aggressively in order to reduce right ventricular
afterload and mitigate right ventricular failure.
Myocardial infarction in the SCD population results from microvascular
vessel occlusion and thus coronary angiography is typically normal 7 . Supportive
care including hydration, supplemental oxygen therapy, and blood transfusion may
be initiated; however, exchange transfusion appears to be the definitive therapy
during severe coronary ischemia. Exchange transfusion to replace Hb S with normal
adult hemoglobin (Hb A) results in reduced microvascular viscosity, inhibition of
the inflammatory cascade, and restoration of the intrinsic nitric oxide pathway 8 .
Patients with SCD frequently present for anesthesia and surgery. An
understanding of the pathophysiology of this disease is critical to provide optimal
care. Perioperative transfusion has been shown to decrease both vaso-occlusive
and cardiac complications in patients undergoing low and medium risk surgery 9 . A
transfusion threshold of 10 g/dl is generally recommended; however, the need for
exchange transfusion and reduced Hb S level is less clear. Conservative transfusion
(maintain Hgb of 10 g/dl), compared to aggressive transfusion (maintain Hgb ≥10
g/dl and exchange transfusion to decrease Hb S <30%), results in 50% less blood
administration and similar complication rates in low to moderate risk surgery 10 .
Major cardiac surgery has been undertaken utilizing both aggressive exchange
transfusion and conservative transfusion protocols with similar complication rates
11,12

.
In patients with SCD and co-existing cardiac disease, a conservative

transfusion strategy to a target Hgb of 10 g/dl should be undertaken. Although

aggressive exchange transfusion may significantly reduce Hb S content, the risk of
blood product administration and volume overload must be reconciled in this
population. Those with underlying pulmonary hypertension, diastolic dysfunction,
or cardiomyopathy, require titrated transfusion and volume administration to avoid
exacerbation of right heart failure or malignant arrhythmias.
Sickle Cell Trait
Sickle cell trait (SCT) is a carrier state of the Hb S mutation occurring in 1.6%
of the US population 13 . Patients with SCT have a higher incidence of urologic
disease including: hematuria, chronic kidney disease, and renal medullary
carcinoma. A small percentage of these patients may display some vaso-occlusive
phenomenon; however, cardiovascular manifestations of SCD are absent and life
expectancy is typically normal. Patients with SCT presenting for surgery and
anesthesia should be managed according to their underlying co-morbidities; no
discrete management due to their status as a SCT carrier is indicated.

Anemia of Chronic Disease
Anemia of chronic disease (ACD) is typically a mild anemia with a
normocytic, normochromic profile primarily due to reduced red blood cell
production. ACD (Hgb <12 g/dl for female, Hgb < 13 g/dl for male) is associated
with increased age, diabetes, renal insufficiency, chronic immune activation, and
cardiac disease; present in 10% of those with coronary disease and as high as 79%
of patients with advanced heart failure 14-16 . In the general population,

observational studies have shown the non-inferiority of restrictive transfusion
protocols (compared with more liberal targets) in the perioperative period;
however, less robust clinical data exists for patients with perioperative anemia and
advanced cardiac disease. One study evaluated the natural history of anemia,
following a subset of anemic patients who refused blood transfusion in the
perioperative period. In those patients with co-existing cardiac disease, the refusal
of blood products was associated with an increased risk of death. 17 A randomized
pilot trial of 110 anemic patients with acute coronary syndrome or stable angina
undergoing cardiac catheterization revealed greater than twice the risk of
myocardial infarction, unscheduled revascularization, or death within 30 days when
treated with a restrictive (transfusion for symptomatic anemia or Hbg <8 g/dl)
transfusion protocol 18 . However, recent registry data further obfuscates the
decision whether or not to transfuse these patients; data have shown an increased
risk of cardiovascular morbidity with as little as one unit of red blood cell
transfusion during the perioperative period 19 . In support of restrictive transfusion
practices, a post-hoc analysis of a subset of 796 patients with known coronary
disease from a large, randomized, controlled trial of hip fracture patients
randomized to restrictive (Hbg <8 mg/dl or symptomatic anemia) or liberal (Hbg <
10 mg/dl) transfusion found similar 30-day mortality rates between the two groups
20,21

. In addition, subgroup analysis of patients with cardiovascular disease from

the Transfusion Requirement in Critical Care (TRICC) trial found no difference in 30
day, 60 day, ICU, or in-hospital mortality when randomized to restrictive (Hbg 7.09.0 g/dl) or liberal transfusion (Hbg 10.0-12.0 g/dl) 22,23 . Even in the setting of

acute coronary syndrome liberal transfusion is not without risk, as a greater degree
of complications related to heart failure has been observed in anemic patients 24 .
While patients with ongoing ischemia may benefit from transfusion to
restore myocardial oxygen delivery, the treatment of anemia in those patients with
CAD or severe heart failure should be approached in a methodical fashion based
upon underlying symptomatology, with a focus on end-organ perfusion and
oxygenation. Physical exam (mental status, urine output), lab monitoring (arterial
lactate, acid/base status), and physiologic monitoring (heart rate, blood pressure,
cardiac index) should all be used to optimize goal directed transfusion therapy in
this complex patient population.

Platelet Abnormalities
Thrombocytosis
Essential thrombocytosis (ET) is a rare disorder affecting approximately 3/
1,000,000 patients and is associated with both thrombosis and hemorrhage. Acute
coronary thrombosis may occur in up to 9.4% of patients with ET 25 . Age, smoking,
hypertension, hyperlipidemia, history of thrombotic events, duration of
thrombocytosis, and platelet count >1,500,000 /μL are associated with increased
thrombotic risk 26,27 . Patients with existing risk factors and a history of occlusive
CAD requiring stents or open revascularization should be treated aggressively with
a platelet lowering regimen to decrease the likelihood of stent thrombosis or

recurrent thrombotic occlusion. Hydroxyurea has been utilized in both ET and
polycythemia vera; and, when compared to control, decreases both platelet count
and thrombotic events in those patients at high risk for thrombotic complications
from thrombocytosis 28 . Strategies to decrease platelet count, generally below
600,000/μL, have been proven to reduce thrombosis 27,28 . Aspirin and hydroxyurea
should be continued throughout the perioperative period in patients with ET. Highrisk patients, especially those with a history of CAD, should be aggressively managed
with hydroxyurea to a target platelet count <600,000/μL in order to decrease the
incidence of thrombotic complications. If signs of acute coronary syndrome
develop, emergent cardiac catheterization is indicated, as the inciting lesion should
be assumed to be occlusive coronary thrombosis until proven otherwise.
Idiopathic Thrombotic Purpura
Immune thrombocytopenic purpura (ITP) is an acquired deficiency of both
platelet count and function. ITP may be classified as either primary (idiopathic) or
secondary (typically due to infection such as hepatitis C, human immunodeficiency
virus, or other autoimmune syndromes such as systemic lupus erythematosus).
Thrombocytopenia in ITP is caused by antibodies to platelet antigens resulting in
decreased platelet lifespan and impaired platelet production. Circulating platelets
are often large and immature, increasing the risk of thrombotic events 30 . Although
rare, coexisting ITP and CAD has been managed by either traditional coronary
artery bypass or percutaneous intervention; however, both pose significant
management dilemmas. Open revascularization is associated with increased
bleeding risk due to thrombocytopenia, whereas stent implantation is complicated

by the need for post-intervention antiplatelet therapy. IVIG and steroid therapy,
coupled with perioperative platelet transfusion, has been used with acceptable
results; however, in those with ITP both open revascularization and percutaneous
intervention are associated with a moderate increase in bleeding 31 . The
preponderance of percutaneous interventions in these patients have utilized bare
metal stents in an effort to limit the duration of post-intervention antiplatelet
therapy 31,32 . A critical assessment of the balance of thrombosis prevention and
bleeding risk must be achieved. Aspirin and clopidogrel have been used
successfully; however, GP IIb/IIIa inhibitors are associated with uncontrolled
bleeding and should be avoided 33,34 . Post intervention antiplatelet agents can be
used until the platelet count falls below 20,000/μL or clinical bleeding occurs.
Thrombotic Thrombocytopenic Purpura
Thrombotic thrombocytopenic purura (TTP) is a rare and often fatal
disorder characterized by thrombocytopenia, hemolytic anemia, renal failure, and
mental status changes. The incidence of TTP in the general population is
approximately 3.7/1,000,000 however, following percutaneous coronary
intervention the incidence is much higher due to antiplatelet induced TTP 35 . TTP
has been reported in be 1/4,814 patients treated with ticlopidine 36 . Clopidogrel
has a safer side effect profile, however reports of TTP following administration exist
37

. Early diagnosis and treatment of antiplatelet induced TTP is essential as

mortality approaches 67% without prompt plasmapharesis 36 .

Anticoagulation for Cardiac Devices

Artificial Valves
Artificial heart valves may be implanted for acute or chronic valvular
dysfunction, resulting in stenotic or regurgitant heart disease. Two main classes of
devices are mechanical valves and bioprosthetic valves. Bioprosthetic valves may
be either a cadaveric homograft or a xenograft composed of porcine or bovine
pericardium mounted on a stent. Although the lifespan of bioprosthetic valves is
generally reduced compared with mechanical valves, use of the tissue material
precludes the need for anticoagulation unless special circumstances arise. In
contrast, mechanical valves are composed of pyrolytic carbon and last an indefinite
period of time. However, due to the high rate of thrombosis, mechanical valves
require aggressive long-term anticoagulation. According to the AHA/ACC
guidelines, patients with a mechanical valve in the mitral position should be
anticoagulated to a target median INR of 3.0 38 . Due to an accelerated transvalvular
flow pattern, the target median INR of a valve in the aortic position in those without
thrombotic risk factors (atrial fibrillation, left ventricular dysfunction,
hypercoagulable state, previous thrombotic event) is 2.5

38

. Although major

guidelines differ in their specific recommendation, aspirin, in addition to warfarin, is
generally recommended in those without increased bleeding risk

38-40

.

Anticoagulation therapy in preparation for non-cardiac surgery must take
into account both the bleeding risk of surgery and the thrombotic risk of abruptly
discontinuing anticoagulation. In general, minor dental or cutaneous procedures
may be accomplished without interruption of anticoagulation; however, if the
surgical site is not amenable to local hemostasis or major surgery is planned, a

preoperative INR <1.5 is desirable. Warfarin should be discontinued 5-6 days prior
to surgical intervention and anticoagulant bridging with a heparin analogue is
indicated.
On rare occasions, patients on chronic anticoagulation for mechanical heart
valves may suffer from warfarin overdose. This is typically manifest by an elevated
INR and frequently results from medication mismanagement or a change in
absorption pharmacokinetics. If no significant bleeding occurs, warfarin can be held
and oral vitamin K administered until target INR is reached. In those with severe
bleeding, prothrombin complex concentrates or fresh frozen plasma may be used to
expeditiously normalize the INR. Complications from severe bleeding generally
outweigh the risk of valve thrombosis. Anticoagulation can be safely interrupted
for 7-14 days even in those at high risk for thromboembolic events

41

.

Pregnant patients with mechanical heart valves pose multiple challenges.
Parturients are hypercoagulable due to changes in blood viscosity, decreased
fibrinolysis, and upregulation of clotting factors. All pregnant patients with artificial
heart valves should be deemed “high risk” as the percentage of pregnancies ending
with both a live mother and child is approximately 81%

42

. Adequate

anticoagulation to prevent mechanical valve thrombosis must be balanced against
the risks of bleeding and teratogenicity of the anticoagulant. In a large registry
series 4.5% of such patients experienced mechanical valve thrombosis with half of
the events occurring in the first trimester

42

. Anticoagulation regimens in the first

trimester remain a matter of debate, as warfarin has been proven to be superior to
heparin analogues for thrombosis prophylaxis; however concerns for teratogenicity,

miscarriage (<24 weeks), and late fetal death (>24 weeks) exist

42

. Multiple

medication regimens have been studied including warfarin, unfractionated heparin,
and low molecular weight heparin. Current guidelines suggest either administration
of low dose (<5mg/day) warfarin or discontinuation of warfarin in the first
trimester

38

. If resumed, complete discontinuation of warfarin is indicated after 36

weeks in preparation for delivery. Anticoagulant coverage can be provided during
warfarin-free periods; or, alternatively maintained for the duration of pregnancy
with unfractionated or low molecular weight heparin. Regardless of the medication
choice; pregnancy in this patient population is best managed by a multi-disciplinary
team and the risk/benefit of anticoagulant medications must be discussed with the
patient.
Ventricular Assist Device
A left ventricular assist device (LVAD) can be utilized in three clinical
scenarios: 1) acute ventricular failure as a bridge to recovery; 2) chronic ventricular
failure as a bridge to heart transplantation; or 3) for permanent implantation in
those not suitable for heart transplantation. All LVADs fall into one of two
physiologic categories based on how blood is circulated through the device:
pulsatile or non-pulsatile. Non-pulsatile, or continuous flow, LVADs are smaller in
size, operate silently, and have greater durability when compared to pulsatile flow
LVADs

43

.

Careful consideration of the anticoagulation status in patients with an LVAD
is important for optimal management. Thrombus formation within the device,
reported to occur between 2-12% at 24 months, can lead to embolic events or LVAD

failure 44 . LVAD patients are anticoagulated with a regimen consisting of antiplatelet agents and warfarin. Target median INR varies between centers from 2.02.5

43

.
Major bleeding may occur in patients with an LVAD secondary to aggressive

anticoagulation, hemolysis, and down regulation of clotting factors. Although the
etiology is not yet completely understood, many continuous-flow LVADs cause
reduced levels of von Willebrand factor, which may further increase the risk of
bleeding. The need to reverse or withhold anticoagulation depends on the severity
and location of hemorrhage. Prothrombin complex concentrates or fresh frozen
plasma can be administered to reverse warfarin. Anticoagulation therapy should
immediately resume when the risk of thrombosis outweighs the risk of further
bleeding.
The extended lifespan of new generation LVADs, coupled with their use for
destination therapy, has resulted in a large proportion of these patients presenting
for elective, non-cardiac surgery. In patients without additional indication for
anticoagulation (atrial fibrillation, left ventricular thrombus) cessation of warfarin
5-6 days before surgery and continuation of aspirin has reduced the need for
perioperative blood transfusion without an increase in thrombosis

45

. In patients at

high risk for thrombosis, anticoagulation bridging with a heparin analogue is
indicated. Warfarin anticoagulation can be safely resumed in the postoperative
period when bleeding risk has subsided.

Heart Failure with Reduced Ejection Fraction
Heart failure is associated with significant morbidity and mortality from
thromboembolic events leading to stroke, myocardial infarction, deep vein
thrombosis, and pulmonary embolus. The pathophysiology of thromboembolism in
heart failure is primarily related to blood stasis within the left ventricle, endothelial
dysfunction, and increased platelet activation. The addition of anticoagulant and/or
antithrombotic therapy in those with coexisting atrial fibrillation or previous
thromboembolic event is recommended; however, anticoagulant therapy for
patients in sinus rhythm with reduced ejection fraction is less clear. Multiple
randomized controlled trials have compared the use of warfarin, aspirin, and
clopidigrel in this patient population with conflicting results 46-48 . Aspirin has been
associated with increased risk for hospitalization and gastrointestinal bleeding;
however, this may be due to an as yet undefined interaction with ACE inhibitors

49

.

Baseline warfarin use has been associated with a reduction in all-cause mortality
and acute coronary syndrome; however, the rate of major bleeding is increased
when compared with aspirin or clopidogrel

49

. Antiplatelet and antithrombotic use

in patients with normal sinus rhythm and reduced ejection fraction should be
dictated based upon underlying co-morbidities and heart failure pathology.
Although controversial, aspirin may be of benefit in patients with underlying
coronary disease and heart failure secondary to ischemic cardiomyopathy.
Alternatively, warfarin can be used to decrease thrombosis risk and improve
intermediate morbidity and mortality in those with reduced ejection fraction and

normal cardiac rhythm.; however, therapy should be reserved for only patients at
low risk for bleeding complications.

Conclusion
Patients with concomitant hematologic and cardiac issues represent
challenges to everyone involved in their perioperative care. An understanding of
the pertinent pathophysiology, the appropriate therapy and the risks are essential.
In the end, management decisions should be based on a thoughtful discussion with
other involved providers and a balanced approach that explicitly addresses the risk
and benefit of each intervention.
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